Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Here's Why Shire PLC Stock Fell 10% in August
Here's Why Shire PLC Stock Fell 10% in August
Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence.....
TheMotleyFool 
0 07.09.17
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top....
TheMotleyFool 
0 07.09.17
GlaxoSmithKline Is Wasting Money Paying a Dividend
GlaxoSmithKline Is Wasting Money Paying a Dividend
As a general rule, I love companies that pay big dividends -- and British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) pays some of the best dividends on the planet. That said, there's one....
TheMotleyFool 
0 01.09.17
Why Intra-Cellular Therapies Is Skyrocketing Today
Why Intra-Cellular Therapies Is Skyrocketing Today
Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage biopharma focused on diseases of the central nervous system, rose more than 26% as of 11:35 a.m. EDT Wednesday. The big jump came in....
TheMotleyFool 
0 23.08.17
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs
TheMotleyFool 
0 11.08.17
Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
Despite upbeat recent developments, shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) fell 15.3% during Wednesday's session. The biotech reported solid progress with clinical-stage candidates
TheMotleyFool 
0 09.08.17
Dividendeneinnahmen im Juli 2017
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
Armer_Charlie 
0 06.08.17
Why AstraZeneca plc Stock Broke Down in July
Why AstraZeneca plc Stock Broke Down in July
Big Pharma stocks don't usually drop by double-digits over the course of a month, but that's exactly what happened to British pharma giant AstraZeneca plc (NYSE: AZN) in July. Due to the late-stage
TheMotleyFool 
0 04.08.17
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
The numbers didn't lie: Gilead Sciences (NASDAQ: GILD) posted pretty good second-quarter results. While revenue and earnings fell compared to the prior-year period, the big biotech still managed to
TheMotleyFool 
0 31.07.17
Why AstraZeneca Stock Is Crashing Today
Why AstraZeneca Stock Is Crashing Today
British pharma giant AstraZeneca's (NYSE: AZN) comeback story took a major blow this morning after the company reported that the all-important Mystic trial assessing Imfinzi (durvalumab) in
TheMotleyFool 
0 27.07.17
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
Amicus Therapeutics (NASDAQ: FOLD) will be able to submit its Fabry disease drug Galafold to the FDA for consideration, a reversal of fortune that sent shares skyrocketing earlier this week. While
TheMotleyFool 
0 14.07.17
Atossa Genetics: Ein rätselhafter Kurssprung!
Atossa Genetics: Ein rätselhafter Kurssprung!
Liebe Leser, bei Atossa Genetics aus Seattle, Washington stehen die Zeichen derzeit auf Hoffnung. Das Papier legte Mitte letzter Woche einen Zwischenspurt ein und gewann zeitweise rund 35....
Robert_Sasse 
0 13.02.17
AstraZeneca: Wettbewerb durch Generika!
AstraZeneca: Wettbewerb durch Generika!
Liebe Leser, letzte Woche überschlugen sich die Nachrichten bei AstraZeneca (AZ), denn ganz ähnlich wie überall im Pharmabereich leidet der Konzern unter dem Verlust von Patenten, die für....
Robert_Sasse 
0 01.01.17
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
Liebe Leser, frühere Kassenschlager wie Nexium, Crestor und Seroquel haben ihren Patentschutz verloren und stehen im Wettbewerb mit preisgünstigeren Generika. Das drückt auf die Ergebnisse. In....
Robert_Sasse 
0 23.12.16
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
Liebe Leser, das britische Pharmaunternehmen GlaxoSmithKline (GKS) macht gemeinsame Sache mit einem Tochterunternehmen der Google-Mutter Alphabet. Wie der Gesundheitskonzern erklärte, werde man gemeinsam
Robert_Sasse 
0 02.08.16
Shire und Baxalta: Der große Tag rückt näher
Shire und Baxalta: Der große Tag rückt näher
Lieber Leser, Baxalta hat jüngst Datum für eine außerordentliche Aktionärsversammlung bekannt gegeben. Am 27. Mai sollen die Baxalta-Anleger darüber entscheiden, ob sie das Übernahmeangebot von Shire akzeptieren.
Robert_Sasse 
0 20.04.16
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AMENDMENT
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AMENDMENT
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AMENDMENT
eqs_en 
0 18.11.20
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc
eqs_en 
0 03.11.20
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q1 2024 Earnings CallApr 25, 2024, 6:45 a.m. ET

Operator

Continue reading

Source Fool.com

TheMotleyFool 
0 25.04.24
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.: https://g.foolcdn.com/editorial/images/764848/scientists-happy.jpg
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.

Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and

TheMotleyFool 
0 13.02.24
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET

Andy Barnett

Continue reading

Source Fool.com

TheMotleyFool 
0 08.02.24
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?: https://g.foolcdn.com/editorial/images/757523/two-investors-meet-and-discuss.jpg
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?

It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge

TheMotleyFool 
0 10.12.23
Is Now the Right Time to Buy AstraZeneca Stock?: https://g.foolcdn.com/editorial/images/757516/two-investors-consult-papers-and-laptop.jpg
Is Now the Right Time to Buy AstraZeneca Stock?

With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's

TheMotleyFool 
0 10.12.23
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant: https://g.foolcdn.com/editorial/images/755562/doctor-giving-a-patient-medication.jpg
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant

Weight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo

TheMotleyFool 
0 22.11.23
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock: https://g.foolcdn.com/editorial/images/755206/healthcare-lab-treatment-research-scientist.jpg
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock

U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes. If

TheMotleyFool 
0 17.11.23